Patients who completed the initial 28-week double-blind period (n=116) of the PRM-151-202 trial were eligible to participate in the open-label extension study (n=111). The 76-week results of this open-label extension study were published in the Lancet Respiratory Medicine during Prof. Ganesh Raghu’s (University of Washington, Seattle, USA) presentation. Long-term treatment with PRM-151 was well tolerated and the effects on percentage of predicted FVC and 6-min walking distance were persistent on continuation and positive in patients who crossed over from placebo [1, 2].
Recombinant human pentraxin-2 (PRM-151), also known as serum amyloid P, has been shown to reduce fibrosis in preclinical and early trial settings. Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with a median survival of 3-5 years after diagnosis. Currently available anti-fibrotic medical interventions retard but d...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Type-2 Inflammation in Asthma Next Article
Aclidinium Bromide Delays COPD Exacerbation without Increased MACE Risk »
Table of Contents: ATS 2019
Treatable Traits in Chronic Inflammatory Airway Disease: Back to Basics
Critical Care Medicine
Pulmonary Vascular Disease and Interstitial Lung Disease
Paediatric Pulmonary Medicine
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.